Skip Navigation


Hum. Reprod. Advance Access originally published online on April 7, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
19/5/1176    most recent
deh235v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Tesarik, J.
Right arrow Articles by Mendoza, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tesarik, J.
Right arrow Articles by Mendoza, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 19, No. 5, 1176-1180, May 2004
© 2004 European Society of Human Reproduction and Embryology

Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation

Jan Tesarik1,2,5, André Hazout3 and Carmen Mendoza1,4

1 MAR&Gen, Molecular Assisted Reproduction & Genetics, Gracia 36, 18002 Granada, Spain, 2 Laboratoire d’Eylau, 55 Rue Saint-Didier, 75116 Paris, 3 ARCEFAR, 15 rue Faraday, 75017 Paris, France and 4 Department of Biochemistry and Molecular Biology, University of Granada Faculty of Sciences, Campus Universitario ‘Fuentenueva’, 18071 Granada, Spain

5 To whom correspondence should be addressed. e-mail: cmendoza{at}ugr.es

BACKGROUND: Several reports have shown that inadvertent administration of a GnRH agonist in the luteal phase does not compromise pregnancy. Moreover, some studies suggested that, unexpectedly, the embryo developmental potential is improved in these conditions. This prospective controlled study was designed to test this hypothesis. METHODS: In an oocyte donation programme, oocytes from each donor (n = 138) were shared by two recipients, one of whom was given a single dose of a GnRH agonist (0.1 mg triptorelin) 6 days after ICSI, and the other received placebo at the same time. RESULTS: Oocyte recipients treated with GnRH agonist 6 days after ICSI had higher implantation (36.9 versus 25.1%), twin pregnancy (16.7 versus 3.6%), twin delivery (13.8 versus 2.2%) and birth (31.1 versus 21.5%) rates and similar miscarriage and abortion rates as compared with the placebo group. CONCLUSIONS: GnRH agonist administration at the time of implantation enhances embryo developmental potential, probably by a direct effect on the embryo.

Key words: embryo developmental potential/GnRH agonist/implantation/oocyte donation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
B. Ata, K. Yakin, B. Balaban, and B. Urman
GnRH agonist protocol administration in the luteal phase in ICSI-ET cycles stimulated with the long GnRH agonistprotocol: a randomized, controlled double blind study
Hum. Reprod., March 1, 2008; 23(3): 668 - 673.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
A. Sengupta, T. Baker, N. Chakrabarti, J. A. Whittaker, and R. Sridaran
Localization of Immunoreactive Gonadotropin-releasing Hormone and Relative Expression of Its mRNA in the Oviduct During Pregnancy in Rats
J. Histochem. Cytochem., May 1, 2007; 55(5): 525 - 534.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
C. B. Lambalk and R. Homburg
GnRH agonist for luteal support in IVF? Setting the balance between enthusiasm and caution
Hum. Reprod., October 1, 2006; 21(10): 2580 - 2582.
[Full Text] [PDF]

Home page
 Hum ReprodHome page
J. Tesarik, A. Hazout, R. Mendoza-Tesarik, N. Mendoza, and C. Mendoza
Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles
Hum. Reprod., October 1, 2006; 21(10): 2572 - 2579.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
C. Pirard, J. Donnez, and E. Loumaye
GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study
Hum. Reprod., July 1, 2006; 21(7): 1894 - 1900.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
T.G. Hannam
'Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation'
Hum. Reprod., January 1, 2006; 21(1): 324 - 324.
[Full Text] [PDF]

Home page
 Hum ReprodHome page
J. Tesarik, A. Hazout, and C. Mendoza
Reply: Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation
Hum. Reprod., January 1, 2006; 21(1): 324 - 325.
[Full Text] [PDF]

Home page
 Hum ReprodHome page
C. Pirard, J. Donnez, and E. Loumaye
GnRH agonist as novel luteal support: results of a randomized, parallel group, feasibility study using intranasal administration of buserelin
Hum. Reprod., July 1, 2005; 20(7): 1798 - 1804.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.